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Abstract: The crystal structure and in vitro cytotoxicity of
the amphiphilic ruthenium complex [3](PF6)2 are reported.
Complex [3](PF6)2 contains a Ru¢S bond that is stable in the
dark in cell-growing medium, but is photosensitive. Upon
blue-light irradiation, complex [3](PF6)2 releases the choles-
terol–thioether ligand 2 and an aqua ruthenium complex
[1](PF6)2. Although ligand 2 and complex [1](PF6)2 are by
themselves not cytotoxic, complex [3](PF6)2 was unexpected-
ly found to be as cytotoxic as cisplatin in the dark, that is,
with micromolar effective concentrations (EC50), against six
human cancer cell lines (A375, A431, A549, MCF-7, MDA-MB-
231, and U87MG). Blue-light irradiation (l=450 nm,
6.3 Jcm¢2) had little influence on the cytotoxicity of [3](PF6)2
after 6 h of incubation time, but it increased the cytotoxicity
of the complex by a factor 2 after longer (24 h) incubation.
Exploring the unexpected biological activity of [3](PF6)2 in
the dark elucidated an as-yet unknown bifaceted mode of
action that depended on concentration, and thus, on the ag-
gregation state of the compound. At low concentration, it
acts as a monomer, inserts into the membrane, and can de-
liver [1]2+ inside the cell upon blue-light activation. At
higher concentrations (>3–5 mm), complex [3](PF6)2 forms
supramolecular aggregates that induce non-apoptotic cell
death by permeabilizing cell membranes and extracting
lipids and membrane proteins.
Introduction
Collective behavior belongs to the most successful evolution-
ary models in nature; a single bee prick only kills the most sen-
sitive victims, whereas an attack by swarming bees kills an
Asian giant hornet by producing heat.[1] Can this concept of
biological swarming be applied to chemistry? Herein, we dem-
onstrate how the chemical modification of a poorly toxic drug-
like compound with a nontoxic lipophilic ligand leads to
a strong biological response mediated either by individual
molecules or by their supramolecular assemblies.
The drug-like structure of interest is a ruthenium–polypyridyl
complex: [Ru(tpy)(bpy)(OH2)]
2+ ([1]2+ ; tpy=2,2’;6’,2“-terpyri-
dine, bpy=2,2’-bipyridine). For most metallodrugs, specific
DNA and/or protein interactions have been proposed as the
mode of action.[2] In principle, aqua complex [1]2+ is a strong
electrophile and its binding to DNA[3] and proteins,[4] which has
been thoroughly investigated in the past, suggested that such
compounds may be used as an anticancer agent.[3a,b,4] Howev-
er, Reedijk et al. demonstrated that [Ru(tpy)(bpy)Cl]Cl, which in
water hydrolyzes into [1]2+ , is poorly cytotoxic.[3b] Probably,
complex [1]2+ loses its ability to bind to biomolecules and
become cytotoxic before it even enters the cell, by undergoing
quick ligand-exchange reactions with nucleophiles present in
media (Figure S2 in the Supporting Information) ; thus forming
an inactive complex. Exchanging the labile aqua or chloride
ligand with a much more strongly bound ligand, L (e.g. , a thio-
ether-, a nitrile-, or pyridine-based ligand), may prevent such
undesired reactions in the dark. In addition, ruthenium com-
plexes such as [Ru(tpy)(bpy)(L)]2+ are photochemically active
because visible-light irradiation leads to ligand-exchange reac-
tions that do not occur in the dark.[4, 5] Such photosubstitution
reactions have been proposed as a way to trigger the toxicity
of anticancer metallodrugs with spatial and temporal resolu-
tion.[5a,g,h, 6] Likewise, photosubstitution of the protecting
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monodentate ligand L in [Ru(tpy)(bpy)(L)]2+ may activate the
complex by producing [1]2+ inside a cell.
Herein, we report on reactivity and cytotoxicity studies with
compound [3](PF6)2, which is a conjugate of [1](PF6)2 and the
thioether–cholesterol ligand 2 (Figure 1). For metallodrugs, li-
gands can, in principle, be utilized to alter drug-like parame-
ters, for example, solubility and/or stability, or to introduce
functional moieties, such as cancer-cell targeting groups or
linkers to a drug carrier. In [3](PF6)2, the cholesteryl group was
initially proposed as a lipid bilayer anchor to deliver the com-
plex to cancer cells by using liposomes.[7] However, cholesterol
is also lipophilic, which is expected to dramatically change the
partition coefficient (logP)[7b–d] and localization of [3]2+ com-
pared with that of [1]2+ . The biological properties of [3](PF6)2
were studied herein in the absence of any liposome drug-de-
livery system. As shown below, the amphiphilic character of
[3](PF6)2 resulted in an unexpectedly high and nonselective cy-
totoxicity profile against a range of human cancer cell lines.
Chemical biological investigations and in vitro light irradiation
experiments characterized a cell death mechanism that de-
pended on concentration.
Results and Discussion
Compound [3](PF6)2 was synthesized according to previous re-
ports.[7a] Single crystals suitable for X-ray structure determina-
tion were grown by vapor diffusion of diethyl ether into a solu-
tion of the compound in ethyl acetate. The structure con-
firmed the coordination of ligand 2 to ruthenium through the
sulfur atom (Figure 1C). The photochemical release of 2 by the
blue-light irradiation of [3]2+ (l=455 nm, 10.5 mWcm¢2) was
studied in the absence of cells, but under the conditions used
for in vitro toxicity experiments,[8] that is, in Opti-MEM com-
plete cell-growing medium (see composition in the Supporting
Information). Within 8 min of irradiation (5.0 Jcm¢2), a batho-
chromic shift of the metal-to-ligand charge transfer (MLCT) ab-
sorption band of the complex was observed, from lmax=
454 nm for [3]2+ to lmax=480 nm, which was characteristic for
[1]2+ (Figure S3 in the Supporting Information). According to
ESI-MS results, the signal for [3]2+ at m/z 519.6 indeed disap-
peared and an intense signal at m/z 571.3 appeared for [2+
Na]+ (calcd m/z 571.4; Figure S4 in the Supporting Informa-
tion); this demonstrates that the photochemical release of
ligand 2 (Figure 1A) also occurs in the medium.
The cytotoxicity of [1](PF6)2, 2, and [3](PF6)2 was investigated
on six different human cancer cell lines derived from photody-
namic therapy (PDT)-relevant malignant tissues (skin, lung,
brain, and breast ; see the Experimental Section for more de-
tails). Briefly, 24 h after seeding, the cells were incubated with
the compounds for 6 or 24 h, the media was refreshed, and
blue-light irradiation was performed (l=455 nm, 10 min,
6.3 Jcm¢2). Following irradiation, the cells were incubated for
an additional 48 h, and then counted by using the sulforhoda-
mine B (SRB) assay (Figure 2A).[9] When possible, the effective
concentration (EC50) leading to 50% lower cell population
compared to a drug-free control was determined in mm
(Table 1). In the dark, neither 2 nor the aqua complex [1](PF6)2
showed any cytotoxicity. Surprisingly, however, complex
[3](PF6)2 was found very cytotoxic, that is, with micromolar EC50
values for all cancer cell lines tested, whereas cisplatin showed
expected increased cytotoxicity against faster proliferating cells
(e.g. , A375) and decreased cytotoxicity against a slower prolif-
erating cell line (e.g. , MDA-MB-231).[10] Meanwhile, the results
of blue-light photocytotoxicity studies (Figure 2 and Table S1
in the Supporting Information) were intriguing. After 6 h of in-
Figure 1. A) Formation of the active compound [1](PF6)2 through light expul-
sion of the thioether ligand [3](PF6)2. B) Chemical structure of the investigat-
ed thioether–cholesterol ligand 2. C) Displacement ellipsoid plot (50% prob-
ability level) of cationic [3]+ , as observed in its crystal structure at 110(2) K.
Only one of the two crystallographically independent molecules is shown.
Counteranions, hydrogen atoms, and disorder have been omitted for clarity.
Characteristic bond lengths [æ]: Ru1¢N1=2.090(5), Ru1¢N2=2.072(4), Ru1¢
N3=2.081(5), Ru1¢N4=1.976(5), Ru1¢N5=2.065(5), Ru1¢S1=2.3639(14).
Figure 2. A) Logarithmic dose–response curve for A549 lung cancer cells
after treatment for 24 h with 2 (inverted triangles), [Ru(tpy)(bpy)Cl]Cl (trian-
gles), [1](PF6)2 (squares), and [3](PF6)2 (filled dots) in the dark. The empty
dots data points and the dashed curve represent the dose–response curve
for cells treated with [3](PF6)2 and irradiated with blue light (l=455 nm,
10 min, 6.3 Jcm¢2). B) Effective concentrations (EC50 in mm with 95% confi-
dence interval) in the dark and after blue-light irradiation (l=450 nm,
10 min, 6.3 Jcm¢2) of [3](PF6)2 on A549 cancer cells after 6 and 24 h of incu-
bation.
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cubation, the cytotoxicity was barely influenced by irradiation,
whereas after 24 h of incubation the activity increased by
a factor of two. Taken together, the unspecific toxicity of
[3](PF6)2 in the dark suggested that this compound might not
interfere with cell proliferation through DNA binding, whereas
the time-dependent, light-enhanced cytotoxicity suggested an
adenosine triphosphate (ATP)-dependent internalization pro-
cess.
MALDI-MS was used to obtain qualitative information about
drug uptake. An immediate advantage of MALDI-MS compared
with the more usual inductively coupled plasma (ICP) MS tech-
nique is the ease of sample preparation.[11] At several time
points of drug incubation (1, 6, and 24 h), MS spectra were
measured directly from thoroughly washed cells. Furthermore,
the detection limit for [1](PF6)2 and [3](PF6)2 was determined to
be below the applied concentration range (i.e. , below 1 mm,
data not shown). Unlike for ICP-MS, partial speciation was pos-
sible with this technique. MALDI-MS detects monocationic spe-
cies,[12] and in the particular case of [1]2+ leads to the detection
of a unique signal at m/z 490.1,[13] which can be assigned to
[Ru(tpy)(bpy-H)]+ (Figures S6 and S7 in the Supporting Infor-
mation). Because MALDI-MS utilizes UV laser ionization (lexc=
355 nm), the ionization of [3](PF6)2 was followed by photosub-
stitution of ligand 2 and detection of the same signal at m/z
490.1; in other words, it was impossible to distinguish [3]2+
from [1]2+ . However, MALDI-MS conditions are much milder
than those used for ICP-MS analysis, that is, cells were not de-
stroyed before the measurement and molecules were not
atomized during ionization. As a consequence, it was possible
to compare the proportion of cell-based signals to that of
ruthenium-based signals (e.g. , m/z 490.1), which were charac-
terized by their unique isotope patterns.
The ratio of ruthenium to cell signal in MALDI-MS was used
to compare drug uptake (see Figure 3 and Table S2 in the Sup-
porting Information for details). As shown in Figure 3, incuba-
tion with complex [1](PF6)2 resulted in negligible ruthenium
signals, whereas incubation with [3](PF6)2 resulted in a signifi-
cant, time-dependent increase in the ratio of Ru/lipid signals.
The observed difference between [1](PF6)2 and [3](PF6)2 is in
good correlation with their different hydrophobicities,[14] and
indicates different drug–cell interactions. The less hydrophobic
ruthenium–polypyridyl complex [1]2+ was seemingly washed
away from the cells, which suggested that [1](PF6)2 did not
enter the cells, and/or interacted minimally with them. This
result correlates with the low toxicity of this compound. In
contrast, the cholesterol-containing compound [3](PF6)2 was al-
ready found in higher quantities in the cells after 1 h of incu-
bation, which indicated increased drug uptake compared with
[1](PF6)2.
For cells treated with [3](PF6)2, the influence of light irradia-
tion, which is accompanied by the in vitro formation of [1]2+ ,
is indicated by the white bars in Figure 3. The ruthenium-
based MALDI-MS intensity significantly decreased after light ir-
radiation (see also Figure S7 in the Supporting Information in
comparison with Figure S6). If the ruthenium species remained
inside the cell after irradiation, and thus, were not washed
away, a similar value for the ruthenium signals would have
been expected under dark and irradiated conditions. Surpris-
ingly, 85% of the ruthenium-based signals disappeared when
light irradiation was performed after 6 h of incubation, and
roughly 50% when it was performed after 24 h of incubation.
These results implied that after 6 h of incubation the light-in-
duced ligand exchange reaction shown in Figure 1a released
[1]2+ outside the cell into the medium, which was washed
away before the MALDI-MS analysis was performed. Therefore,
compound [3]2+ must stick initially in the biological membrane
with the cholesterol ligand inserted in the outer leaflet of the
cell membrane, and the ruthenium ion pointing into the
media. The higher ruthenium intensity observed when light ir-
radiation was performed after a longer (24 h) incubation time
further implied that [3](PF6)2 flipped in a time-dependent
manner into the inner leaflet of the cell membrane, probably
in a similar but slower manner to that for cholesterol.[15] These
observations are consistent with the negligible effect of light
irradiation after 6 h. It is only when the ruthenium complex
has flip-flopped towards the cytosol (i.e. , after 24 h) that light
irradiation, and with it the intracellular formation of [1]2+ (the
“bee”), leads to additional cytotoxicity by one of the (un-
known) intracellular interactions with DNA or proteins.
The unspecific cytotoxicity in the dark, however, cannot be
explained with this model. A more collective mode of action,
similar to that of a swarm of bees, was found to be responsible
for the cytotoxicity of [3](PF6)2 at higher concentrations in the
dark. First, standard chemical biological experiments were con-
ducted to analyze the type of cell death. A DNA ladder experi-
Table 1. Cytotoxicity of [1](PF6)2, 2, and [3](PF6)2 in the dark given as ef-
fective concentrations (EC50) in mm with a confidence interval of 95%.
Cell line EC50 [mm]
[1](PF6)2 2 [3](PF6)2 Cisplatin
A375 >150 >60 6.51.1 1.90.2
A431 >150 >60 6.20.9 3.60.6
A549 >150 >60 5.20.4 4.30.7
MCF-7 >150 >60 5.01.1 2.60.4
MDA-MB-231 >150 >60 6.00.8 >25
U87Mg >150 >60 6.52.4 5.91.0
Figure 3. Ratio of Ru-based/cell-based signals observed by MALDI-MS after
different cell treatment conditions. Black bars correspond to samples kept in
the dark, white bars to irradiated cells (l=454 nm, 10 min, 6.3 Jcm¢2). Incu-
bation times before refreshing of medium and irradiation are indicated.
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ment (Figure S9 in the Supporting Information)
showed that [3](PF6)2 acted independently of caspas-
es.[16] Second, cell cycle analysis (Figure S10 in the
Supporting Information) confirmed that [3](PF6)2 did
not interfere with proliferation,[9, 17] and third, dye-ex-
clusion assays[18] implied a concentration-dependent
loss of cell-membrane integrity (Figure S11 in the
Supporting Information). All these observations indi-
cated that a necrotic form of cell death was induced
by [3](PF6)2 at 10 mm in the dark. This hypothesis was
confirmed by a flow cytometric annexin V-propidium
iodide assay (Figure S12 in the Supporting Informa-
tion).[19] In addition, optical microscopy imaging re-
vealed an unusual cell-size modulating activity of
[3](PF6)2. With increasing concentrations, the cells
shrunk to the size of the nuclei, without losing the
outer cell membrane (Figure 4). In addition, signifi-
cant debris was observed at concentrations of [3](PF6)2 higher
than 10 mm. These debris particles could be stained with the
protein-binding dyes SRB[9] (Figure 4c) and trypan blue[18b] (Fig-
ure S11D in the Supporting Information), but not with the
DNA-specific dye DAPI.[20]
Stimulated Raman scattering (SRS) microscopy experi-
ments[21] were conducted to look for the presence of lipids in
those debris particles. Briefly, SRS signals were measured in
living cells by utilizing the lipid-specific CH2 stretching vibra-
tion at n˜=2850 cm¢1 (an example is depicted in Figure 5B).
The investigated cells showed the typical lipid distribution:
a bright signal for the cell membrane, endoplasmic reticulum,
Golgi apparatus and endosomal compartments, but no signal
in the lipid-poor nuclear region.[22] The debris particles, which
formed after treatment with high concentrations of [3](PF6)2,
were already visible in the bright-field image (Figure 5A), and
were between 1.0–2.5 mm in size. In the lipid-sensitive SRS ex-
periments, this debris gave a strong resonance signal (indicat-
ed with arrows in Figure 5B). Altogether, these results implicat-
ed that the debris particles were lipid–protein aggregates ex-
tracted from the cell membrane, which explained why [3](PF6)2
induced a cell-line-unspecific, DNA-independent cell death
above 5 mm. Detergents, such as sodium dodecyl sulfate (SDS),
Triton-X 100, or cetyltrimethylammonium bromide (CTAB), are
also known for their ability to extract lipid–protein aggregates
from cell membranes and are visible as debris particles (Fig-
ure S8 in the Supporting Information).[23] Thus, we hypothe-
sized that [3](PF6)2, which consists of a charged ruthenium
polypyridyl head group and a lipophilic tail, might behave as
a metal–organic surfactant capable of aggregating above a cer-
tain concentration and affecting the cell membrane.
To confirm this hypothesis, the critical aggregate concentra-
tion (CAC) of [3](PF6)2 was measured by dynamic light scatter-
ing (DLS).[23] The CAC of a compound is the concentration at
which further addition of amphiphilic molecules does not
change the monomer concentration. Above this concentration,
the monomer molecules are in equilibrium with supramolec-
ular aggregates of finite size.[24] A CAC of 3.5 (0.5) mm was
found for [3](PF6)2 (Figures S13 and S14 in the Supporting In-
formation), which is a prototypical characteristic of molecular
detergents.[25] Thus, complex [3](PF6)2 is able to form aggre-
gates of typically 68 (10) nm (zav, according to DLS), which, in
contact with cells, are susceptible to form mixed assemblies
that also contain cellular lipids and proteins, in analogy to
non-metalated surfactants.[23,26]
Additional experiments were conducted to gain a deeper
understanding of these interactions. First, the time evolution
of the A549 cell population treated with [3](PF6)2 was studied
and compared with those for cisplatin, staurosporine, Triton-X,
and SDS. As shown in Figure S5 in the Supporting Information,
after compound withdrawal, the cell population initially treat-
ed with [3](PF6)2 recovered, as observed for Triton-X 100 or
SDS. In contrast, for cisplatin- or staurosporine-treated cells, no
recovery was observed after withdrawing the drug-loaded
media. The recovery of cell proliferation for cells treated with
[3](PF6)2 correlated well with cell cycle analysis by means of
flow cytometry (Figure S10 in the Supporting Information), in
which no difference between the control and the treated cell
populations was found 24 h after media refreshment.
Figure 4. Micrographs of A549 cells (40Õ). 4’,6-Diamidino-2-phenylindole
(DAPI) staining (of DNA) of A) untreated cells and B) cells treated with
[3](PF6)2 (25 mm). C) Micrograph of cells after treatment with [3](PF6)2
(25 mm), fixation (trichloroacetic acid (TCA), 10%), and SRB staining (to visu-
alize proteins).
Figure 5. A) Bright-field micrograph of A549 cells (32Õ) treated with [3](PF6)2 (10 mm).
B) Stimulated Raman scattering (SRS) image of the same cell at n˜=2850 cm¢1, primarily
selective for lipids. Blue arrows indicate some of the lipid-containing debris particles. The
intensity scale for the SRS signal (8-bit) is given as inset. The scale bar is 20 mm.
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In a separate experiment, the dependence of the cytotoxici-
ty (EC50) on the cell population was measured. As shown in
Figure S15 in the Supporting Information, the EC50 of [3](PF6)2
decreased with an increased number of cells, whereas chang-
ing the cell density did not influence the EC50 of cisplatin.
Thus, an increased number of cell membranes diminishes the
toxicity of [3](PF6)2. Taken together, these facts are consistent
with the hypothesis of a thermodynamically driven mode of
action for high concentrations of [3](PF6)2 in the dark.
Conclusion
Our understanding of the cytotoxic activity of [3](PF6)2 relies
on two separate modes of action (Figure 6). At low concentra-
tions relative to the CAC, monomers of [3](PF6)2, like single
bees, insert quickly into the outer leaflet of the cell membrane.
The flip-flop to the inner leaflet, which leads to internalization,
occurs in a slower manner. After a short (6 h) incubation time,
the light-induced release of membrane-impermeable species
[1]2+ occurs outside the cell without biological consequences.
After a prolonged incubation time (24 h), the same photoreac-
tion leads to the release of [1]2+ inside the cell, where an un-
known target is reached that may coordinate to ruthenium,
eventually resulting in a more lethal signal. This first mode of
action is similar to that of recently reported ruthenium com-
pounds.[27] At concentrations above the CAC of (3.50.5) mm,
however, complex [3](PF6)2 most likely behaves like a swarm by
forming aggregates. When the ratio between these aggregates
and the cell membrane lipids is high enough, thermodynamic
forces lead to the generation of holes in the cell membrane
(Figure S11 in the Supporting Information) and, at the highest
concentrations tested (10–25 mm), to lipid–protein extraction
of the cell membrane and formation of ternary aggregates
containing cell lipids, membrane proteins, and [3](PF6)2 (Fig-
ures 4 and 5 and Figure S8 in the Supporting Information). Be-
cause it is simply based on the lipid/detergent equilibrium, this
second mode of action is neither cell-line specific, nor en-
hanced by light irradiation. On the contrary, light irradiation
transforms [3]2+ back to ligand 2 and the aqua complex [1]2+ ,
that is, it destroys the amphiphilic character of [3]2+ and its
ability to form toxic aggregates.
Such a bifaceted mode of action is unprecedented among
metallodrugs, which are usually supposed to target nuclear
DNA, mitochondrial membranes, or proteins. The complex be-
havior of compound [3](PF6)2 is due to the combination of its
amphiphilic character and light sensitivity. This type of com-
pound opens up two separate roads for drug delivery. First, as
a monomer they can be used as prodrugs to release the toxic
part (herein [1]2+) by light irradiation. Second, as aggregate-
forming molecules they may be used as light-sensitive drug
carriers that, similar to a Trojan horse, can release a lipophilic
load under visible-light irradiation, which annihilates its amphi-
philic character. In addition, these results should serve as
a warning for the design of future metallodrugs. Increasing lip-
ophilicity is often used as a way to increase cellular uptake.[28]
However, we showed herein that, by combining a charged
metal-based head with a fatty tail, self-aggregation became
possible, which radically changed not only how much of the
compound penetrated into the cell, but also the mode of
action of the compound. Finally, the possibility of extracting
lipid–protein aggregates with an inorganic surfactant may
offer significant advantages in the field of proteomics and lipi-
domics, due to the unique methods (e.g. , MALDI-MS) available
for detecting inorganic compounds.
Figure 6. Proposed mode of action of [3](PF6)2. Treatment with concentrations above the CAC leads to lipid–protein extraction, and eventually to necrotic cell
death. Treating the cells with concentrations below the CAC leads to insertion of the compound in the cell membrane, followed by a time-dependent inter-
nalization. A significant photon-enhanced effect was only observed after 24 h incubation, that is, after internalization of [3]2+ , and thus, when the resulting
active complex [1]2+ could interact with an (unknown) intracellular target.
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Experimental Section
General
1H NMR spectra were recorded by using a Bruker DPX-300 spec-
trometer; chemical shifts are indicated in ppm relative to tetrame-
thylsilane (TMS). Electrospray mass spectra were recorded on a Fin-
nigan TSQ-quantum instrument by using an ESI technique. DLS
was performed with a Nanosizer instrument from Malvern operat-
ing at lirr=633 nm. A Tecan M1000 PRO plate reader was used for
fluorescence and absorbance measurements in 96-well plates.
Images and data were processed with Origin Pro, FCS Express,
Prism 5.0, ChemDraw, Gimp 2.0, and Microsoft Excel software.
Synthesis and crystal growth
The synthesis of all described ligands and complexes was per-
formed as reported previously. 3b-(2-{2-[2-(Methylthio)ethoxy]e-
thoxy}ethoxy)cholesterol (2 ; CAS-Nr: 1373125-91-7) was described
by Bahreman et al.[5d] [Ru(tpy)(bpy)(Cl)]Cl and [1](PF6)2 were synthe-
sized according to previous reports,[5b, 29] and [3](PF6)2 was prepared
as described by Askes et al.[7a] Single crystals of [3](PF6)2 were ob-
tained by slow recrystallization through the vapor diffusion of di-
ethyl ether into a solution of the complex in ethyl acetate. Long
and thin crystals with a ruby color were obtained that were suita-
ble for X-ray crystal structure determination.
Single-crystal X-ray crystallography
All reflection intensities were measured at 110(2) K by using a Su-
perNova diffractometer (equipped with an Atlas detector) with
CuKa radiation (l=1.54178 æ) under the program CrysAlisPro (Ver-
sion 1.171.36.32 Agilent Technologies, 2013). The program CrysAlis-
Pro (Version 1.171.36.32 Agilent Technologies, 2013) was used to
refine the cell dimensions and for data reduction. The structure
was solved with the program SHELXS-2013[30] and was refined on
F2 with SHELXL-2013 (Sheldrick, 2015). Analytical numeric absorp-
tion corrections based on a multifaceted crystal model were ap-
plied by using CrysAlisPro (Version 1.171.36.32 Agilent Technolo-
gies, 2013). The temperature of the data collection was controlled
by using the system Cryojet (manufactured by Oxford Instruments).
The H atoms were placed at calculated positions by using the in-
structions AFIX 13, AFIX 23, AFIX 43, or AFIX 137 with isotropic dis-
placement parameters with values 1.2 or 1.5 times Ueq of the at-
tached C atoms.
The structure was partly disordered. The fragment C52B!C59B/
C52’!C59’ (C53B excluded) was disordered over two orientations,
and the occupancy factor of the major component of the disorder
was refined to 0.561(7). The contribution of two disordered ethyl
acetate solvent molecules was removed from the final refinement
by using SQUEEZE[5f] (details are provided in the CIF file). The abso-
lute configuration was established by anomalous dispersion effects
in diffraction measurements on the crystal. The Flack parameter re-
fined to 0.009(7).
Crystal data for [3](PF6)2 : Mr=1329.34; orange–red plates; 0.48Õ
0.38Õ0.02 mm3 ; monoclinic; P21 (no. 4) ; a=37.5901(3), b=
10.59806(7), c=16.68304(13) æ; b=100.6353(8)8 ; V=6532.05(9) æ3 ;
Z=4; Dx=1.352 gcm
¢3 ; m=3.389 mm¢1; Tmin¢Tmax : 0.341–0.935;
77205 reflections were measured up to a resolution of (sinq/
l)max=0.62 æ
¢1; 22930 reflections were unique (Rint=0.0464), of
which 21312 were observed [I>2s(I)] ; 1552 parameters were re-
fined by using 223 restraints; R1/wR2 [I>2s(I)]: 0.0387/0.1017; R1/
wR2 (all reflns): 0.0422/0.1046; S=1.035; residual electron density
was found between ¢0.47 and 0.64 eæ¢3.
CCDC-1430105 contains the supplementary crystallographic data
for this paper. These data are provided free of charge by The Cam-
bridge Crystallographic Data Centre.
Stability assays
In a mixture of [D6]DMSO/PBS (7:1): Complex [3](PF6)2 was dis-
solved in a 7:1 mixture of [D6]DMSO/phosphate-buffered saline
(PBS) mixture and immediately subjected to 1H NMR spectroscopy
measurements (300 MHz, 128 scans). The tube was placed in an in-
cubator set at 37 8C, and additional spectra were measured after
26, 49, and 73 h in the dark. No changes could be measured (see
Figure S1 in the Supporting Information), which proved that
[3](PF6)2 was thermally stable under such conditions.
In Opti-MEM : The thermal stability of complexes [Ru(tpy)(bpy)Cl]Cl,
[1](PF6)2, and [3](PF6)2 under cell culture conditions (Opti-MEM
complete, 37 8C) was investigated by measuring the evolution of
the UV/Vis spectra in the dark by using a Tecan M1000PRO reader
(Figure S2 in the Supporting Information). After 6 h, the first two
compounds had reacted with medium components, whereas
[3](PF6)2 was essentially unchanged.
Cell culturing: Reagents and cells
Cells (A-375, human malignant melanoma; A-431, human epider-
moid carcinoma; A549, human lung carcinoma; MCF7, human
mammary gland adenocarcinoma; MDA-MB-231, human mammary
gland adenocarcinoma; U-87 MG, human glioblastoma grade IV)
were distributed by the European Collection of Cell Cultures
(ECACC), and purchased through Sigma Aldrich. Dulbecco’s modi-
fied Eagle medium (DMEM, with and without phenol red, without
glutamine), 200 mm glutamine-S (GM), TCA, glacial acetic acid, SRB,
and tris(hydroxylmethyl)aminomethane (tris base) were purchased
from Sigma Aldrich. Fetal calf serum (FCS) was purchased from Hy-
clone. Penicillin and streptomycin were purchased from Duchefa
and were diluted to a 100 mgmL¢1 solution of penicillin/strepto-
mycin (P/S). Trypsin and Opti-MEMÒ (without phenol red) were pur-
chased from GibcoÒ Life Technologies. Trypan blue (0.4% in 0.81%
sodium chloride and 0.06% potassium phosphate dibasic solution)
was purchased from BioRad. Plastic disposable flasks and 96-well
transparent plates were obtained from Sarstedt. The 96-well black
plates were from Greiner Bio-one (5665–5090). Eight-chamber mi-
croscope slides, NuncÒ Lab-TekÒ II Chamber slideTM systems, were
purchased from Sigma Aldrich. RNAse A and proteinase K (from Tri-
tirachium album) were purchased from Sigma Aldrich. The 1-kb
Plus DNA ladder was purchased from Fisher Scientific. Tris-acetate–
ethylenediaminetetraacetic acid (EDTA; TAE) buffer (pH 8) was pre-
pared as a 50Õ stock solution and diluted to 1Õ prior to usage.
DNA-loading buffer was prepared as a 10 mL stock solution by
using glycerol (3 mL), a solution of EDTA (1 mL, 0.5m, pH 8), and
methylene blue (5 mg). Cell lysis buffer (100 mm Tris-HCl, pH 8,
20 mm EDTA, 0.8% SDS) was freshly prepared. Mass spectrometry
experiments were performed on a Synapt G2-Si MALDI-TOF mass
spectrometer (Waters Corporation, Milford, MA), equipped with
a l=355 nm laser. Before the measurements, the instrument was
calibrated by using red phosphorus (Acros Organics). A 0.5m solu-
tion of 2,5-dihydroxybenzoic acid (DHB; Sigma) in methanol was
used as a matrix. Mass spectra were acquired in positive mode.
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General cell culturing
Cells were purchased and upon receipt were cultured for working
and frozen stocks. Each cell line was cultured in DMEM complete,
with phenol red, supplemented with 8.0% v/v FCS, 0.2% v/v P/S,
and 0.9% v/v GM. Cells were cultured in 25 cm2 flasks and were
split into a new passage at 70–80% confluence (approximately 3Õ
per week). Flasks were incubated at 37 8C with a CO2 level of 7.0%.
Media was changed every second day. For all irradiation experi-
ments, Opti-MEMÒ media, supplemented with 2.5% FCS, 0.2% v/v
P/S, and 1% v/v GM (later on called OMEM complete) was used.
Cells were passaged for 4–8 weeks. SRB was purchased from Alfa
Aesar GmbH&Co under the tradename Kiton Red S.
96-LED irradiation setup
A 96 light-emitting diode (LED) array, described in depth by Hop-
kins et al. ,[8] allowed the irradiation of a 96-well plate at 37 8C and,
in parallel, maintained dark control under otherwise identical con-
ditions. The light of the LED array had a wavelength of lmax=
(45422) nm, and at a voltage of 28.9 V the power at the bottom
of each well was (10.50.7) mWcm¢2.
Cell-free light irradiation of [3](PF6)2 in 96-well plates
In a 96-microtiter black plate, solutions of [3](PF6)2 (25 mm) in Opti-
MEM complete media (200 mL) were irradiated in triplicate at 37 8C
by using the LED setup. After 20, 15, 12, 10, 8, 6, 4, 2, and 0 min of
irradiation, the UV/Vis spectrum of each well was measured by
using a Tecan M1000pro plate reader (Figure S3 in the Supporting
Information). The samples were submitted to ESI-MS measure-
ments to confirm the light-induced release of ligand 2 from the
complex upon irradiation in Opti-MEM complete (Figure S4 in the
Supporting Information). Overall, under cell-growing conditions,
8 min or 5 Jcm¢2 of blue-light irradiation was enough to almost
fully activate 5 nmol of the Ru complex [3]2+ .
Dark cytotoxicity and phototoxicity on human cancer cell
lines
The cytotoxicity of compounds 2, [Ru(tpy)(bpy)(Cl)]Cl, [1](PF6)2, and
[3](PF6)2 was evaluated by using the SRB microculture colorimetric
assay. In short, exponentially growing cells were seeded in Opti-
MEMÒ (without phenol red, w/2.5% FCS, P/S, and GM) into 96-well
plates at t=0 at the appropriate cell densities (A375=7000 cells/
well, A431=8000 cells/well, A549=5000 cells/well, MCF-7=
8000 cells/well, MDA-MB-231=12000 cells/well, U87Mg=
6000 cells/well) to prevent confluence of the cells during the ex-
periment. At t=6 or 24 h, the cells were treated with serial dilu-
tions of each compound in Opti-MEM, depending on the expected
EC50 value after 6 or 24 h of incubation. For 2, [Ru(tpy)(bpy)(Cl)]Cl,
and [1](PF6)2, the concentration series was 1.50, 7.50, 15.00, 30.00,
75.00, and 150.00 mm ; for [3](PF6)2 it was 0.25, 1.25, 2.50, 5.00,
12.50, and 25.00 mm. The final DMSO concentration per well never
exceeded 0.75%, which was nontoxic to the cells.[31] After 6 or 24 h
of incubation with the drug-loaded media, the media was aspirat-
ed and replaced by fresh, warm (37 8C) media; the plates were
kept on a heating mat during media refreshing to avoid a signifi-
cant drop in temperature for the cells, and to insure a temperature
of at least 33 8C during light irradiation. Light irradiation was per-
formed for 10 min (l=454 nm, 6.3 J cm¢2) by using the LED-based,
96-well plate irradiation setup described by Hopkins et al.[8] A du-
plicate plate was treated the same way, but without light irradia-
tion and was further referred to as the dark control.
The percentages of surviving cells relative to compound-free wells
were determined 72 h after the beginning of drug exposure, that
is, at t=96 h, by using the SRB assay.[9] Briefly, cells were fixed by
using cold TCA (10% w/v) and maintained at 4 8C for 4–48 h. Once
fixed, TCA was removed from the wells, plates were gently washed
5Õ with water, air dried, stained by using 100 mL SRB (0.6% w/v
SRB in 1% v/v acetic acid) for 30–45 min, washed with approxi-
mately 300 mL acetic acid (1% v/v) 5Õ times, air dried, and the dye
was then solubilized by using 10 mm tris base. The absorbance at
l=510 nm was read by using a M1000 Tecan Reader. The SRB ab-
sorbance data were used to evaluate the viable cell population in
Excel and GraphPad Prism. The absorbance data from three wells
(technical replicates, nt=3) for each cell line and concentration
were averaged. Relative cell populations were calculated by divid-
ing the average absorbance of the irradiated wells by the average
absorbance of the dark control. Three biological replicates (nb=3)
of each treatment and cell line were completed. The averages of
the biological replications were plotted as relative cell population
versus log (concentration in mm) with standard error of each con-
centration. For each cell line, the EC50 was calculated by fitting the
logarithmic dose–response curves through nonlinear regression
with a fixed Y maximum (100%) and minimum (0%) relative cell
population, and a variable Hill slope; this resulted in the simplified
two parameter Hill slope equation by using PRISM 5.0.
MALDI-MS
Qualitative uptake experiments were performed through MALDI-
MS experiments. Cells of cell-line A549 were seeded in Opti-MEMÒ
(without phenol red, w/2.5% FCS, P/S, and GM) in an eight-cham-
ber glass slide (25000 cells/well). Treatment with solutions of
[1](PF6)2, [3](PF6)2, or [Ru(tpy)(bpy)(Cl)]Cl for 24 h, 6 h, 1 h, or 1 min
was performed 24–48 h after seeding. After incubation with the
drug, the supernatant media was aspirated, the cells were washed
gently 3Õ with PBS, fresh media was added, and the cells were ir-
radiated with blue light by using the same 96-LED array as that
used for irradiating 96-well plates (l=455 nm, 10 min, 6.3 Jcm¢2,
37 8C). An identical eight-chamber slide was prepared, but left in
the dark as a control. After removing the chamber (on top of the
glass slide) and drying the cell monolayer under ambient condi-
tions, a 0.5m solution of DHB matrix in methanol was applied by
means of a pipette, and the samples were submitted to the MALDI
SYNAPT G2-Si mass spectrometer.
To analyze the data, the individual signal height of the cell and the
drug-specific signals were first measured. Because the mass spectra
from the untreated cell culture (control) showed a different pat-
tern, depending on the treatment (light irradiated vs. dark probe,
compare Figure S6A vs Figure S7A* in the Supporting Informa-
tion), several lipid signals were chosen to decrease a potential bias
due to irradiation. After summing up the height of the cell- and
drug-specific signals, the ratio between the heights was calculated
to analyze the distribution of the investigated sample, and to even-
tually be able to determine the uptake indirectly. In Table S2 in the
Supporting Information, the list of chosen signals and assignments,
as far as possible, is given.
Microscopic investigation of living cells in the presence of
surfactants in the dark
Cells were seeded in a 96-well plate according to the cytotoxicity
assay. After 24 h of incubation, the medium was removed and the
cells were treated with increasing concentrations of the indicated
drugs in Opti-MEM complete. Optical microscopy images were re-
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corded after 24 h of drug incubation in the dark (37 8C, 7% CO2) at
the indicated magnifications.
Dye-exclusion assay : The supernatant media was removed, the
cells were treated with a diluted solution of trypan blue (0.25%),
and the cells submitted to microscopic investigations (see Fig-
ure S11 in the Supporting Information).
DAPI staining : The supernatant media was removed, the cells
were stained for 10 min with a solution of DAPI (0.01 mgmL¢1),
and then the cells were imaged.
DNA-laddering experiment
Approximately 500000 cells of the cell-line A549 were seeded in
cell culture flasks (25 cm2) and grown in DMEM (10% FCS, 0.2% P/
S, 0.9% GM). After 24 h, the supernatant media was removed and
the nonconfluent cell monolayer was reloaded with substance-
loaded medium (or a blank fresh medium as a control). After 24–
72 h, the supernatant medium was collected and the cell monolay-
er was washed with PBS. The combined media and PBS were cen-
trifuged (1500 rpm, 5 min, Eppendorf 5702 centrifuge). The pellet
of dead cells was gently suspended in PBS (1 mL) and centrifuged
again (1500 rpm, 5 min, 278 K, Eppendorf Centrifuge 5418). PBS
was removed and lysis buffer (30 mL, 0 8C, 10 min) was added. Then
RNAse (100 mgmL¢1, 10 mL) was added and the cells were incubat-
ed for 10 min on ice followed by a prolonged incubation at 37 8C
for 2 h. To finally digest the cell proteins, the cell pellet was treated
with protein kinase K (10 mL) at 52 8C for 12 h. The extract was
mixed with DNA-ladder dye (10 mL) and analyzed by gel electro-
phoresis (2% agarose loaded with 10 mL ethidium bromide
(10 mgmL¢1), 150 mV, 2 h, TAE buffer). The DNA bands were ana-
lyzed (see Figure S9 in the Supporting Information) by using a UV
transilluminator (BioRad).
Cell cycle investigation by flow cytometry
Approximately 500000 cells of the cell-line A549 were seeded in
cell culture flasks (25 cm2) and grown in DMEM complete. After
24 h, the supernatant media was removed and the nonconfluent
cell monolayer reloaded with substance-loaded medium (or
a blank fresh medium as a control). After 24–72 h of drug incuba-
tion, the supernatant medium was submitted to the DNA-ladder-
ing experiment (see above), whereas the living cells were washed
and harvested with trypsin. After centrifugation (1500 rpm, 5 min,
Eppendorf Centrifuge 5702), the supernatant was withdrawn, the
cells resuspended with PBS (1 mL), and centrifuged (1500 rpm,
5 min, Eppendorf Centrifuge 5418). After additional washing with
PBS, the cells were fixed by adding ice-cold ethanol (70%) drop-
wise to the cells stored on ice. For thorough fixation and permea-
bilization, the cells were stored at least for 24 h at ¢20 8C. There-
after, the cells were washed with PBS buffer (with Mg2+ and Ca2+ ,
containing 1% bovine serum albumin (BSA), and 0.1% NaN3, 3Õ
1 mL, 1000 rpm, Eppendorf Centrifuge 5418). Several cell suspen-
sions were adjusted to the same cell concentration (ca.
100000 cellsmL¢1), gently suspended in staining buffer (PBS buffer
containing BSA, RNAse, NaN3, and PI analogue reported by Darzyn-
kiewicz et al.[17]), and incubated for 30 min at room temperature in
the dark. Analyses were performed by using a Beckman Coulter
Quanta machine; collecting data from the FL2 channel. The cell
population of interest was selected by plotting EV versus FL1. For
each cell cycle distribution 100000 events were collected. The dis-
tribution was calculated by using FCSexpress software by applying
the method of Dean and Jett.[32] Representative histograms and
compiled results are shown in Figure S10 in the Supporting Infor-
mation.
SRS microscopy
The cell lipids were visualized by utilizing SRS microscopy. Cells of
the cell-line A549 were seeded in Opti-MEMÒ (without phenol red,
w/2.5% FCS, P/S, and GM) in an eight-chamber glass slide
(5000 cells/well). After 24 h, cells were treated with solutions of
[3](PF6)2 (10 mm) for 24 h. After incubation with the drug, the su-
pernatant media was aspirated, the cells were washed gently with
PBS, and fresh media was added. Before SRS measurements, the
media was aspirated, the chamber (on top of the glass slide) was
removed, and a cover glass was mounted. The experimental setup
for SRS imaging was mainly as described previously.[21d] In brief,
laser light at l=1064.4 nm (80 MHz, 8 ps) was intensity-modulated
at 3.636 MHz with an acousto-optic modulator and overlapped
with l=816.7 nm light for imaging at n˜=2850 cm¢1. A Zeiss laser
scanning microscope with a 32Õ objective (C-Achroplan W, NA=
0.85) was used to image samples with non-descanned detection in
forward scattering mode at 512Õ512 pixels with a pixel dwell time
of 177 ms. Time-averaged laser powers on the sample were 10 mW
for the pump beam and 20 mW for the Stokes beam. The signal
was amplified with a homebuilt transimpedance amplifier before
demodulation in a lock-in amplifier (SR844 Stanford Research Sys-
tems). The X-phase output at a sensitivity of 1 mV was supplied to
the ZEN microscopy software for image recording and processing.
Determination of the CAC
The CAC was measured by using a fixed-angle light-scattering
technique.[25a,33] Duplicates of a concentration series of [3](PF6)2 (0
to 10 mm) in distilled water were prepared and submitted to DLS
measurements (Malvern Nanosizer, l=633 nm). The attenuation
factor was fixed to 11. For the analysis, the intensity of the scat-
tered light (in kilocounts per second) was plotted against the con-
centration of [3](PF6)2 (see Figure S13 in the Supporting Informa-
tion), according to an application note from Malvern.[25b]
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